Journal Mobile Options
Table of Contents
Vol. 14, No. 1, 2002
Issue release date: June 2002
Cerebrovasc Dis 2002;14:33–41

Hydroxyethyl Starch for Hypervolemic Hemodilution in Patients with Acute Ischemic Stroke: A Randomized, Placebo-Controlled Phase II Safety Study

Rudolf J.
Klinik für Neurologie der Universität zu Köln, Köln, Deutschland

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Hypervolemic hemodilution (HH) with hydroxyethyl starch (HES) significantly increases cerebral blood flow and thus may reduce ischemic tissue damage in the penumbra zones when given within the therapeutic time window. The objective of this study was to investigate the safety of a 10% solution of HES 130/0.4 versus 0.9% saline solution in acute ischemic stroke by the incidence of adverse events (AEs). Methods: In a controlled, double-blind, randomized, multicenter, phase II, parallel-group study, 106 patients with acute ischemic stroke received high-dose HH with HES 130/0.4 or placebo within 6 h of symptom onset with a randomization ratio of 2:1 in favor of HES therapy. Results: There were no significant differences between the groups with regard to the incidence of the specific AEs (cardiovascular events, bleeding complications, allergic reactions) assessed over days 1–30, or mortality over days 1–8. In addition, global tests of efficacy showed a trend towards a better functional outcome with HES therapy; however, the study was not designed to prove efficacy. Conclusions: High-dose HH with HES or NaCl was generally safe and well tolerated. Safety profiles were similar for the two treatment groups, and there was a nonsignificant trend towards a better functional outcome with HES therapy.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Wood JH, Simeone FA, Kron RE, Snyder LL: Experimental hypervolemic hemodilution: Physiologic correlations of cortical blood flow, cardiac output and intracranial pressure with fresh blood viscosity and plasma volume. Neurosurgery 1984;14:709–723.
  2. Tu YK, Heros RC, Candia G, Hyodo A, Lagree K, Callahan R, Zervas NT, Karacostas D: Isovolemic hemodilution in experimental focal cerebral ischemia. 1. Effect on hemodynamics, hemorheology and intracranial pressure. J Neurosurg 1988;69:72–81.

    External Resources

  3. Heiss WD, Prosenz P, Tschabitscher H, Lasek C, Herles HJ: Effect of low molecular dextran on total cerebral blood flow and on regional flow within ischemic brain lesions. Eur Neurol 1972;8:129–133.

    External Resources

  4. Matthews WB, Oxbury JM, Grainger KMR, Greenhall RCD: A blind controlled trial of dextran 40 in the treatment of ischemic stroke. Brain 1976;99:193–206.

    External Resources

  5. Strand T, Asplund K, Eriksson S, Haag E, Lithner F, Wester PO: A randomized controlled trial of hemodilution therapy in acute ischemic stroke. Stroke 1984;15:980–989.
  6. Multicenter trial of hemodilution in acute stroke. I. Results in the total patient population. Scandinavian Stroke Study Group. Stroke 1987;18:691–699.
  7. Multicenter trial of hemodilution in acute stroke. II. Subgroup analyses. Scandinavian Stroke Study Group. Stroke 1988;19:464–471.

    External Resources

  8. Haemodilution in acute stroke: Results of the Italian haemodilution trial. Italian Acute Stroke Study Group. Lancet 1988;i:318–320.
  9. Hypervolemic hemodilution treatment of acute stroke. Results of a randomized multicenter trial using pentastarch. The Hemodilution in Stroke Study Group. Stroke 1989;20:317–320.
  10. Aichner FT, Fazekas F, Brainin M, Pölz W, Mamoli B, Zeiler K: Hypervolemic hemodilution in acute ischemic stroke. The Multicenter Austrian Hemodilution Stroke Trial (MAHST). Stroke 1998;29:743–749.
  11. Asplund T: Hemodilution in acute stroke. Cerebrovasc Dis 1991;1(suppl):129–138.
  12. Mast H, Marx P: Neurological deterioration under isovolemic hemodilution with hydroxyethyl starch in acute cerebral ischemia. Stroke 1991;22:680–683.
  13. Goslinga H, Eijzenbach H, Heuvelmans JHA, van der Laan de Vries E, Melis VMJ, Schmid-Schönbein H, Bezemer PD: Custom-tailored hemodilution with albumin and crystalloids in acute ischemic stroke. Stroke 1992;23:181–188.
  14. Schimetta W: Therapeutische Hämodilution: Eine Übersicht. Perfusion 1995;7:228–246.
  15. Kroemer H, Haass A, Muller K, Jäger H, Wagner EM, Heimburg P, Klotz U: Haemodilution therapy in ischaemic stroke: Plasma concentrations and plasma viscosity during long-term infusion of dextran 40 or hydroxyethyl starch 200/0.5. Eur J Pharmacol 1987;31:705–710.
  16. Lyden P, Brott T, Tilley B, Welch KMA, Mascha EJ, Levine S, Haley EC, Grotta J, Marler J: Improved reliability of the NIH Stroke Scale using video training. NINDS TPA Stroke Study Group. Stroke 1994;25:2220–2226.
  17. Jennett B, Bond M: Assessment of outcome after severe brain damage – a practical scale. Lancet 1975;ii:480–484.
  18. Van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J: Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604–667.
  19. Mahoney FI, Barthel DW: Functional evaluation: The Barthel index. Md State Med J 1965;14:61–65.

    External Resources

  20. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581–1587.
  21. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet 1998;352:1245–1251.
  22. Jonas S: Anticoagulant therapy in cerebrovascular disease: Review and meta-analysis. Stroke 1988;19:1043–1048.

    External Resources

  23. Koller M, Haenny P, Hess K, Weniger D, Zangger P: Adjusted hypervolemic hemodilution in acute ischemic stroke. Stroke 1990;21:1429–1434.
  24. Waitzinger J, Bepperling F, Pabst G, Opitz J, Müller M, Baron JF: Pharmacokinetics and tolerability of a new hydroxyethyl starch (HES) specification (HES (130/0.4)) after single-dose infusion of 6% or 10% solutions in healthy volunteers. Clin Drug Invest 1998;16:151–160.
  25. Grond M, Stenzel C, Schmülling S, Rudolf J, Neveling M, Lechleuthner A, Schneweis S, Heiss WD: Early intravenous thrombolysis for acute ischemic stroke in a community-based approach. Stroke 1998;29:1544–1549.
  26. Adams HP Jr, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Kwiatkowski T, Lyden PD, Marler JR, Torner J, Feinberg W, Mayberg M, Thies W: Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation 1996;94:1167–1174.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50